Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma

• Published in: Journal of Nuclear Medicine Vol. 65; no. 4; pp. 586 - 592
• Main Authors: Lin, Fanching, Clift, Renee, Ehara, Takeru, Yanagida, Hayato, Horton, Steven, Noncovich, Alain, Guest, Matt, Kim, Daniel, Salvador, Katrina, Richardson, Samantha, Miller, Terra, Han, Guangzhou, Bhat, Abhijit, Song, Kenneth, Li, Gary
• Format: Journal Article
• Language: English
• Published: United States Society of Nuclear Medicine 01.04.2024
• Subjects: Affinity; Binding; Biodistribution; Cancer; Glycoproteins; Heparan sulfate proteoglycans; Hepatocellular carcinoma; Internalization; Liver cancer; Lutetium isotopes; Peptides; Pharmaceuticals; Plasma resonance; Radiochemistry; Radioisotopes; Tumors; Xenografts; Xenotransplantation; GPC3; HCC; theranostics; actinium; targeted radiotherapy
• ISSN: 0161-5505; 1535-5667; 2159-662X
• DOI: 10.2967/jnumed.123.266766

Glypican-3 (GPC3) is a membrane-associated glycoprotein that is significantly upregulated in hepatocellular carcinomas (HCC) with minimal to no expression in normal tissues. The differential expression of GPC3 between tumor and normal tissues provides an opportunity for targeted radiopharmaceutical therapy to treat HCC, a leading cause of cancer-related deaths worldwide. : DOTA-RYZ-GPC3 (RAYZ-8009) comprises a novel macrocyclic peptide binder to GPC3, a linker, and a chelator that can be complexed with different radioisotopes. The binding affinity was determined by surface plasma resonance and radioligand binding assays. Target-mediated cellular internalization was radiometrically measured at multiple time points. In vivo biodistribution, monotherapy, and combination treatments with Lu or Ac were performed on HCC xenografts. RAYZ-8009 showed high binding affinity to GPC3 protein of human, mouse, canine, and cynomolgus monkey origins and no binding to other glypican family members. Potent cellular binding was confirmed in GPC3-positive HepG2 cells and was not affected by isotope switching. RAYZ-8009 achieved efficient internalization on binding to HepG2 cells. Biodistribution study of Lu-RAYZ-8009 showed sustained tumor uptake and fast renal clearance, with minimal or no uptake in other normal tissues. Tumor-specific uptake was also demonstrated in orthotopic HCC tumors, with no uptake in surrounding liver tissue. Therapeutically, significant and durable tumor regression and survival benefit were achieved with Lu- and Ac-labeled RAYZ-8009, as single agents and in combination with lenvatinib, in GPC3-positive HCC xenografts. Preclinical in vitro and in vivo data demonstrate the potential of RAYZ-8009 as a theranostic agent for the treatment of patients with GPC3-positive HCC.